The Lynx Group
Cholangiocarcinoma News

Institutional Review Data Indicate That Actionable Genetic Testing and Personalized Medicine in Hepatobiliary and Pancreatic Cancers Is Rarely Applied

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Real-world data indicate that genetic testing and personalized medicine is rarely applied in the community setting for patients with hepatobiliary and pancreatic cancers.

Given the importance of early identification of actionable genetic alterations for practice of precision medicine in patients with hepatobiliary and pancreatic cancers, a retrospective analysis was conducted to analyze the incidence of actionable genetic alterations in a large community health system, the results of which were reported at the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium.

An institutional review was performed to identify patients with hepatocellular carcinoma (HCC), intrahepatic CCA, extrahepatic CCA, gallbladder carcinoma, or pancreatic adenocarcinoma who underwent molecular panel testing in the Oncology Precision Medicine database at Advocate Aurora Health, Milwaukee, WI. Patients were stratified by cancer type, and treatment course was analyzed using swimmer plots.

A total of 456 patients diagnosed with HCC, intrahepatic CCA, extrahepatic CCA, gallbladder carcinoma, or pancreatic adenocarcinoma were identified in the Oncology Precision Medicine database. Of these, 88 (19.3%) patients completed molecular testing and were included in the analysis. Of the 88 patients, 18 (20.4%) patients had intrahepatic or extrahepatic CCA, 2 (2.3%) patients had HCC, 5 (5.7%) patients had gallbladder carcinoma, and 63 (71.6%) patients had pancreatic adenocarcinoma. In total, actionable mutations were identified in 8 (9.1%) patients. Of these, 5 patients had BRAF mutations (pancreatic adenocarcinoma, N = 2; intrahepatic or extrahepatic CCA, N = 2; gallbladder carcinoma, N = 1); 2 patients subsequently began targeted therapy, 1 had a PFS of 2.5 months and the other discontinued secondary to toxicity. Three patients harbored BRCA1/2 mutations, all in patients with pancreatic adenocarcinoma (3 of 63 [4.8%]); however, they did not receive BRCA-targeted therapies.

These data indicate that only a minority of patients with hepatobiliary and pancreatic cancers undergo genetic testing in a real-world clinical practice setting, underscoring the need for early and systematic genetic testing to identify actionable genetic alterations that may allow early initiation of appropriate targeted therapy to improve patient outcomes.

Source: Bellini G, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 570.

Related Items

Ivosidenib Approved for Advanced or Metastatic Cholangiocarcinoma
Web Exclusives
Ivosidenib has been approved by the FDA for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
June/July 2021, Vol 2, No 2
Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.
FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma
June/July 2021, Vol 2, No 2
The FDA granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) that harbors an FGFR2 fusion or other rearrangement.
Futibatinib in Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Primary Results of FOENIX-CCA2 Presented at AACR 2021
June/July 2021, Vol 2, No 2
The primary results of the phase 2 FOENIX-CCA2 clinical trial of futibatinib in patients with previously treated intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements were presented by Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Massachusetts General Hospital, Boston, at the 2021 Annual Meeting of the American Association for Cancer Research (AACR).
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
By Loretta Fala
June/July 2021, Vol 2, No 2
Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. Although the exact prevalence of CCA is unknown, CCA is a rare cancer; approximately 8000 new cases of CCA are diagnosed annually in the United States.
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions
By Mitesh J. Borad, MD; Milind M. Javle, MD; Michael Morse, MD, FACP, MHS; Lewis R. Roberts, MB, ChB, PhD
June/July 2021, Vol 2, No 2
On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (FGFR) inhibitors as second-line therapy, and practical approaches to incorporating FGFR inhibitors into the treatment paradigm for the disease.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
December 2020, Vol 1, No 3
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: